제품 수집
제품 세부정보
Synonyms
FLJ18683, T3E, TCRE, CD3E, CD3-epsilon
Source
Biotinylated Human CD3 epsilon, His,Avitag (CDE-H82E1) is expressed from human 293 cells (HEK293). It contains AA Asp 23 - Asp 126 (Accession # P07766-1).
Predicted N-terminus: Asp 23
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 15.5 kDa. The protein migrates as 17-18 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
0.7-1.0 as determined by the SABA assay / HABA assay / binding ELISA.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
SDS-PAGE
Biotinylated Human CD3 epsilon, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Mouse Anti-Human CD3 (SP34-2) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Immobilized Human DLL3, His Tag (Cat. No. DL3-H52H4) at 0.2 μg/mL, add increasing concentrations of Tarlatamab and then add Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 8.21 ng/mL (Routinely tested).
Protocol
Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) at 2 μg/mL, add increasing concentrations of Glofitamab and then add Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 41.71 ng/mL (Routinely tested).
Protocol
Immobilized Human BCMA, Mouse IgG2a Fc Tag (Cat. No. BCA-H5253) at 1 μg/mL, add increasing concentrations of Teclistamab and then add Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 6.23 ng/mL (Routinely tested).
Protocol
Bioactivity-TR-FRET
In this TR-FRET assay, Streptavidin Protein Europium chelate (for TR-FRET) (Cat. No. FRT-TD09) is used as the Donor and Monoclonal Anti-Human IgG Antibody FA-Labeled (for TR-FRET) (Cat. No. FRT-TA02) is used as the Acceptor. Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1), at 0.3125 ng/well, can bind to the Teclistamab with a linear detection range of 8-0.001 μg/mL (Routinely tested).
In this TR-FRET assay, Streptavidin Protein Europium chelate (for TR-FRET) (Cat. No. FRT-TD09) is used as the Donor and Monoclonal Anti-Human IgG Antibody FA-Labeled (for TR-FRET) (Cat. No. FRT-TA02) is used as the Acceptor. Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1), at 0.5 ng/well, can bind to the Glofitamab with a linear detection range of 16-0.008 μg/mL (Routinely tested).
In this TR-FRET assay, Streptavidin Protein Europium chelate (for TR-FRET) (Cat. No. FRT-TD09) is used as the Donor and Monoclonal Anti-Human IgG Antibody FA-Labeled (for TR-FRET) (Cat. No. FRT-TA02) is used as the Acceptor. Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1), at 0.5 ng/well, can bind to the Tarlatamab with a linear detection range of 8-0.004 μg/mL (Routinely tested).
Bioactivity-SPR
Bispecific T-cell Engager captured on Protein A Chip can bind Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1) with an affinity constant of 2.62 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
사용자 리뷰 댓글 남기기
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
배경 소개
프론티어 진행
의약품 개발 진행- 영어 이름：
T-cell surface glycoprotein CD3 epsilon chain
- 카테고리：
- 상장 의약품 수：
4 상세
- 임상 의약품 수：
7 상세
- 최고 개발 단계：
Approved
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
